

# U.S. Biopharmaceutical CMO & CRO Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service (Contract Manufacturing, Contract Research), By Product (Biologics, Biosimilars), And Segment Forecasts, 2023 - 2030

<https://marketpublishers.com/r/U03DC2CF3BCAEN.html>

Date: February 2023

Pages: 122

Price: US\$ 4,950.00 (Single User License)

ID: U03DC2CF3BCAEN

## Abstracts

This report can be delivered to the clients within 2 Business Days

### U.S. Biopharmaceutical CMO & CRO Market Growth & Trends

The U.S. biopharmaceutical CMO & CRO market size is expected to reach USD 16.7 billion by 2030, expanding at a CAGR of 6.1% during the forecast period, according to a new report by Grand View Research, Inc. The contract manufacturing organization (CMO) and contract research organization (CRO) industries have seen significant growth in recent years, particularly in the U.S. This growth is driven by a variety of factors, including the increasing demand for biologics and other complex therapies, the need for more flexible and scalable manufacturing capabilities, and the desire to reduce supply chain risks and costs.

Another factor driving the expansion of CMO and CRO manufacturing facilities in the U.S. is the need for more flexible and scalable manufacturing capabilities. The biopharmaceutical industry is characterized by rapid technological change and changing demands, which can create challenges for companies that have invested heavily in fixed manufacturing assets. By outsourcing to CMOs and CROs, pharmaceutical companies can access manufacturing and research capacity on an as-needed basis, without incurring the fixed costs associated with building and maintaining their own

facilities. This approach allows companies to more quickly and efficiently respond to changes in market demand.

The increased demand for biopharmaceutical research and manufacturing has resulted in CMOs and CROs acquiring existing biopharmaceutical manufacturing and research facilities or building new facilities in their existing plants. This is because the expansion of these facilities increases the capacity to meet the growing demand for biologics and other biopharmaceutical products.

With the U.S. being a major market for biopharmaceuticals, expansion of facilities in this region is crucial for companies to cater to the needs of their customers and stay competitive in the market. For instance, FUJIFILM Diosynth Biotechnologies announced plans to expand their Taxes plant by adding 138,000 sq feet by 2024. This expansion will lead to the construction of a new cGMP production facility that is expected to become operational in 2024. This expansion is expected to double the advanced therapy and vaccine manufacturing capacity of the company in the U.S.

#### U.S. Biopharmaceutical CMO & CRO Market Report Highlights

Mammalian cell line-based bioproduction system is the largest segment and is expected to grow at a CAGR of 6.3% during the forecast period

The contract research service types segment is expected to register the fastest CAGR of 6.9% over the forecast period

The biologics product segment accounted for the largest market share of 82.4% in the year 2022

This can be attributed to the local presence of several contract research service providers in the country. The U.S. has a higher concentration and number of biopharmaceutical CMOs and CROs in comparison with other countries

## Contents

### CHAPTER 1 RESEARCH METHODOLOGY

- 1.1 Market Segmentation & Scope
- 1.2 Market Definition
- 1.3 Information Procurement
  - 1.3.1 Purchased database
  - 1.3.2 GVR's internal database
  - 1.3.3 Secondary sources & third party perspectives
  - 1.3.4 Primary research
- 1.4 Information Analysis
  - 1.4.1 Data analysis models
- 1.5 Market Formulation & Data Visualization
- 1.6 Data Validation & Publishing

### CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Biopharmaceutical CMO & CRO Market Outlook, 2018 - 2030

### CHAPTER 3 INDUSTRY OUTLOOK: MARKET VARIABLES, TRENDS, & SCOPE

- 3.1 Penetration & Growth Prospect Mapping For Contract Manufacturing Service, 2018
- 3.2 Trend Analysis
  - 3.2.1 Source trend
  - 3.2.2 Service trend
  - 3.2.3 Product trend
  - 3.2.4 Regional trend
- 3.3 Biopharmaceutical CMO & CRO Market: Market Dynamics
  - 3.3.1 Market driver analysis
    - 3.3.1.1 Rising investment by CMOs for capacity expansion
    - 3.3.1.2 Commercial success of biopharmaceuticals and consequent increased demand for the biopharmaceuticals
    - 3.3.1.3 Robust biopharmaceuticals pipeline
    - 3.3.1.4 Cost and time-saving benefits offered by contract services
  - 3.3.2 Market restraint analysis
    - 3.3.2.1 Limited outsourcing among well-established biopharmaceutical manufacturers
- 3.4 Key Opportunity Analysis
  - 3.4.1 Rising funds in the biopharmaceutical industry

- 3.4.2 Mergers & acquisition for facility expansion
- 3.4.3 Growing demand for protein therapeutics
- 3.5 Industry Analysis - Porter's
  - 3.5.1 Supplier Power: Substantial number of suppliers for bioprocessing equipment contributes to the low supplier power
  - 3.5.2 Buyer Power: Fragmented nature of the biopharmaceutical industry has led to the moderate bargaining power of buyers
  - 3.5.3 Substitution Threat: High due to the presence of several big pharma companies
  - 3.5.4 New Entrants Threat: Presence of established players coupled with the need for adequate capacity results in a moderate threat of new entrants
  - 3.5.5 Competitive Rivalry: High due to the fragmented nature of the market
- 3.6 Biopharmaceuticals CMO & CRO-SWOT Analysis, By PEST
  - 3.6.1 Political landscape
  - 3.6.2 Economic landscape
  - 3.6.3 Social landscape
  - 3.6.4 Technology landscape
- 3.7 COVID-19 Impact and Reformation Analysis

## **CHAPTER 4 U.S. BIOPHARMACEUTICALS CMO & CRO MARKET: SOURCE ESTIMATES & TREND ANALYSIS**

- 4.1 U.S. Biopharmaceuticals CMO & CRO Market: Source Movement Analysis
- 4.2 Mammalian Source
  - 4.2.1 U.S. mammalian source market, 2018 - 2030 (USD Million)
- 4.3 Non-mammalian Source
  - 4.3.1 U.S. mammalian source market, 2018 - 2030 (USD Million)

## **CHAPTER 5 U.S. BIOPHARMACEUTICALS CMO & CRO MARKET: SERVICE TYPE ESTIMATES & TREND ANALYSIS**

- 5.1 U.S. Biopharmaceuticals CMO & CRO Market: Service Type Movement Analysis
- 5.2 Contract Manufacturing, by service
  - 5.2.1 U.S. contract manufacturing market, 2018 - 2030 (USD Million)
  - 5.2.2 Process development
    - 5.2.2.1 U.S. process development market, 2018 - 2030 (USD Million)
    - 5.2.2.2 Downstream processing
      - 5.2.2.2.1 U.S. downstream processing market, 2018 - 2030 (USD Million)
    - 5.2.2.3 Upstream processing
      - 5.2.2.3.1 U.S. upstream processing market, 2018 - 2030 (USD Million)

### 5.2.3 Fill & finish operations

5.2.3.1 U.S. fill & finish operations market, 2018 - 2030 (USD Million)

### 5.2.4 Analytical & QC testing

5.2.4.1 U.S. analytical & QC testing market, 2018 - 2030 (USD Million)

### 5.2.5 Packaging

5.2.5.1 U.S. contract packaging market, 2018 - 2030 (USD Million)

## 5.3 Contract Research

5.3.1 U.S. contract research market, 2018 - 2030 (USD Million)

### 5.3.2 Oncology

5.3.2.1 U.S. oncology market, 2018 - 2030 (USD Million)

### 5.3.3 Inflammation & immunology

5.3.3.1 U.S. inflammation & immunology market, 2018 - 2030 (USD Million)

### 5.3.4 Cardiology

5.3.4.1 U.S. cardiology market, 2018 - 2030 (USD Million)

### 5.3.5 Neuroscience

5.3.5.1 U.S. neuroscience market, 2018 - 2030 (USD Million)

### 5.3.6 Others

5.3.6.1 U.S. other CRO services market, 2018 - 2030 (USD Million)

## **CHAPTER 6 U.S. BIOPHARMACEUTICALS CMO & CRO MARKET: PRODUCT ESTIMATES & TREND ANALYSIS**

### 6.1 U.S. Biopharmaceuticals CMO & CRO Market: Product Movement Analysis

#### 6.2 Biologics

6.2.1 U.S. biologics market, 2018 - 2030 (USD Million)

##### 6.2.2 Monoclonal Antibodies

6.2.2.1 U.S. monoclonal antibodies market, 2018 - 2030 (USD Million)

##### 6.2.3 Recombinant proteins

6.2.3.1 U.S. recombinant proteins market, 2018 - 2030 (USD Million)

##### 6.2.4 Vaccines

6.2.4.1 U.S. vaccines market, 2018 - 2030 (USD Million)

##### 6.2.5 Antisense, RNAi, & molecular therapy

6.2.5.1 U.S. antisense, RNAi, & molecular therapy market, 2018 - 2030 (USD Million)

##### 6.2.6 Others

6.2.6.1 U.S. other product market, 2018 - 2030 (USD Million)

#### 6.3 Biosimilars

6.3.1 U.S. biosimilars market, 2018 - 2030 (USD Million)

## **CHAPTER 7 COMPETITIVE LANDSCAPE**

## 7.1 Company Profiles

### 7.1.1 Boehringer Ingelheim GmbH

7.1.1.1 Company overview

7.1.1.2 Financial performance

7.1.1.3 Product benchmarking

7.1.1.4 Strategic initiatives

### 7.1.2 LONZA

7.1.2.1 Company overview

7.1.2.2 Financial performance

7.1.2.3 Product benchmarking

7.1.2.4 Strategic initiatives

### 7.1.3 Catalent

7.1.3.1 Company overview

7.1.3.2 Financial performance

7.1.3.3 Product benchmarking

7.1.3.4 Strategic initiatives

### 7.1.4 Rentschler Biotechnologie GmbH

7.1.4.1 Company overview

7.1.4.2 Financial performance

7.1.4.3 Product benchmarking

7.1.4.4 Strategic initiatives

### 7.1.5 Thermo Fisher Scientific Inc

7.1.5.1 Company overview

7.1.5.2 Financial performance

7.1.5.3 Product benchmarking

7.1.5.4 Strategic initiatives

### 7.1.6 AGC Biologics

7.1.6.1 Company overview

7.1.6.2 Financial performance

7.1.6.3 Product benchmarking

7.1.6.4 Strategic initiatives

### 7.1.7 Fujifilm Diosynth Biotechnologies

7.1.7.1 Company overview

7.1.7.2 Financial performance

7.1.7.3 Product benchmarking

7.1.7.4 Strategic initiatives

### 7.1.8 Abzena

7.1.8.1 Company overview

- 7.1.8.2 Financial performance
- 7.1.8.3 Product benchmarking
- 7.1.8.4 Strategic initiatives
- 7.1.9 Samsung Biologics
  - 7.1.9.1 Company overview
  - 7.1.9.2 Financial performance
  - 7.1.9.3 Product benchmarking
  - 7.1.9.4 Strategic initiatives
- 7.1.10 WuXi Biologics
  - 7.1.10.1 Company overview
  - 7.1.10.2 Financial performance
  - 7.1.10.3 Product benchmarking
  - 7.1.10.4 Strategic initiatives
- 7.1.11 AbbVie Inc.
  - 7.1.11.1 Company overview
    - 7.1.11.1.1 DPx
  - 7.1.11.2 Financial performance
  - 7.1.11.3 Product benchmarking
  - 7.1.11.4 Strategic initiatives
- 7.1.12 Charles River Laboratories International, Inc.
  - 7.1.12.1 Company overview
  - 7.1.12.2 Financial performance
  - 7.1.12.3 Product benchmarking
  - 7.1.12.4 Strategic initiatives
- 7.1.13 ICON Plc
  - 7.1.13.1 Company overview
  - 7.1.13.2 Financial performance
  - 7.1.13.3 Product benchmarking
  - 7.1.13.4 Strategic initiatives
- 7.1.14 Parexel International Corporation
  - 7.1.14.1 Company overview
  - 7.1.14.2 Financial performance
  - 7.1.14.3 Product benchmarking
  - 7.1.14.4 Strategic initiatives
- 7.1.15 Labcorp.
  - 7.1.15.1 Company overview
  - 7.1.15.2 Financial performance
  - 7.1.15.3 Product benchmarking
  - 7.1.15.4 Strategic initiatives

## List Of Tables

### LIST OF TABLES

TABLE 1 2020 pipeline of biologics

TABLE 2 Some commercially available biopharmaceuticals and biologics produced using both mammalian & non-mammalian cell lines

TABLE 3 Some commercially available biopharmaceuticals and biologics produced using only mammalian cell lines

TABLE 4 Some biopharmaceuticals produced using *S. cerevisiae*

TABLE 5 Some commercially available biopharmaceuticals and biologics produced using only microbial cell lines

TABLE 6 Some commercially available monoclonal antibody products

TABLE 7 Number of MAbs products by indication area, 2015

TABLE 8 Time and budget requirements for different stages of vaccine development



## List Of Figures

### LIST OF FIGURES

- FIG. 1 Market research process
- FIG. 2 Information Procurement
- FIG. 3 Primary research pattern
- FIG. 4 Market research approaches
- FIG. 5 Value chain-based sizing & forecasting
- FIG. 6 QFD modeling for market share assessment
- FIG. 7 Market segmentation & scope
- FIG. 8 Biopharmaceutical CMO & CRO market outlook, 2018 - 2030
- FIG. 9 Market trends & outlook
- FIG. 10 Market driver relevance analysis (Current & future impact)
- FIG. 11 Number of Reference Products by U.S. Biosimilars Launchable Dates
- FIG. 12 Market restraint relevance analysis (Current & future impact)
- FIG. 13 Risk associated with outsourcing services
- FIG. 14 SWOT Analysis, By Factor (political & legal, economic and technological)
- FIG. 15 Porter's Five Forces Analysis
- FIG. 16 Strategy framework
- FIG. 17 U.S. biopharmaceuticals CMO & CRO market: Source outlook key takeaways
- FIG. 18 U.S. Biopharmaceuticals CMO & CRO market: Source movement analysis
- FIG. 19 U.S. mammalian source market, 2018 - 2030 (USD Million)
- FIG. 20 U.S. non-mammalian source market, 2018 - 2030 (USD Million)
- FIG. 21 U.S. biopharmaceuticals CMO & CRO market: Service type outlook key takeaways
- FIG. 22 U.S. biopharmaceuticals CMO & CRO market: Service movement analysis
- FIG. 23 U.S. contract manufacturing market, 2018 - 2030 (USD Million)
- FIG. 24 U.S. process development market, 2018 - 2030 (USD Million)
- FIG. 25 U.S. downstream processing market, 2018 - 2030 (USD Million)
- FIG. 26 U.S. upstream processing market, 2018 - 2030 (USD Million)
- FIG. 27 U.S. fill & finish operations market, 2018 - 2030 (USD Million)
- FIG. 28 U.S. analytical & QC testing market, 2018 - 2030 (USD Million)
- FIG. 29 U.S. contract packaging market, 2018 - 2030 (USD Million)
- FIG. 30 U.S. contract research market, 2018 - 2030 (USD Million)
- FIG. 31 U.S. oncology market, 2018 - 2030 (USD Million)
- FIG. 32 U.S. inflammation & immunology market, 2018 - 2030 (USD Million)
- FIG. 33 U.S. cardiology market, 2018 - 2030 (USD Million)
- FIG. 34 U.S. neuroscience market, 2018 - 2030 (USD Million)

- FIG. 35 U.S. other CRO services market, 2018 - 2030 (USD Million)
- FIG. 36 U.S. biopharmaceuticals CMO & CRO market: Product outlook key takeaways
- FIG. 37 U.S. biopharmaceuticals CMO & CRO market: Product movement analysis
- FIG. 38 U.S. biologics market, 2018 - 2030 (USD Million)
- FIG. 39 Year-wise annual approvals for MAbs products that are currently marketed in U.S./EU
- FIG. 40 Share of MAbs-related R&D programs at different pipeline phases, 2015
- FIG. 41 U.S. monoclonal antibodies market, 2018 - 2030 (USD Million)
- FIG. 42 Comparison of R&D biotech pipeline expansion for recombinant products
- FIG. 43 U.S. recombinant proteins market, 2018 - 2030 (USD Million)
- FIG. 44 U.S. vaccines market, 2018 - 2030 (USD Million)
- FIG. 45 U.S. antisense, RNAi, & molecular therapy market, 2018 - 2030 (USD Million)
- FIG. 46 U.S. other product market, 2018 - 2030 (USD Million)
- FIG. 47 U.S. biosimilars market, 2018 - 2030 (USD Million)

## I would like to order

Product name: U.S. Biopharmaceutical CMO & CRO Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service (Contract Manufacturing, Contract Research), By Product (Biologics, Biosimilars), And Segment Forecasts, 2023 - 2030

Product link: <https://marketpublishers.com/r/U03DC2CF3BCAEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U03DC2CF3BCAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970